MindImmune Therapeutics

MindImmune Therapeutics Focuses on Developing Products Targeting Immune Drivers of Neurodegenerative Diseases. Its Lead Program, MITI-101, Aims to Halt the Harmful Entry of Peripheral Immune Cells into the Brain in Patients with Alzheimer’s Disease and Other Neurodegenerative Conditions. By Targeting a Key Upstream Mechanism of Neuroinflammation, MITI-101 Has the Potential to Deliver a First-in-Class Therapeutic Breakthrough, Improving Multiple Aspects of Neurodegenerative Diseases.